Ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS) or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer
No prior malignancy of any type (including ductal breast carcinoma in situ [DCIS]) within the past 5 years except for current diagnosis of breast cancer, and any prior diagnosis of basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; patients with a prior history of breast cancer greater than 5 years from study screening may participate in this study
Documentation of mammogram and ultrasound (including ductal carcinoma in situ [DCIS] and invasive cancer) of the diseased breast performed within 56 days prior to registration; mammogram for the unaffected contralateral breast is required within 12 months prior to registration
Curatively treated ductal carcinoma in situ of the breast.
History of ductal carcinoma in situ (DCIS), except for participants treated exclusively with mastectomy >5 years prior to diagnosis of current breast cancer
Adequately treated breast ductal carcinoma in situ
Breast cancer\r\n* Infiltrating ductal carcinoma or ductal carcinoma in situ (DCIS), stage T0, T1, and T2 =< 3.0 cm, N0 and M0\r\n* Patients benefiting from high dose rate brachytherapy (HDR) as either as a boost or accelerated partial breast irradiation regimen
INCLUSION - TREATMENT: Pathologic review shows no evidence of residual disease in the tumor bed (to also include no evidence of residual ductal carcinoma in situ [DCIS])
Histologically confirmed invasive carcinoma or ductal carcinoma in situ (DCIS) of the breast
For the window phase: Patients must have histologically confirmed invasive lobular carcinoma or invasive ductal carcinoma; no central confirmation of histological subtype is necessary for enrollment; patients with mixed invasive ductal and lobular carcinoma are eligible and will be stratified as ductal
Patients with a history of ipsilateral or contralateral ductal carcinoma in situ (DCIS) are eligible
Adequately treated breast ductal carcinoma in situ without evidence of disease
Ductal breast carcinoma in situ (DCIS) only
Ductal carcinoma in situ (DCIS) or invasive epithelial (ductal, medullary, papillary, mucinous [colloid], or tubular histologies)
Pathological diagnosis of Invasive Ductal Breast Cancer or Ductal Carcinoma in Situ requiring mastectomy
Clinical T1N0M0 invasive carcinoma or ductal carcinoma in situ (DCIS) < or equal to 2 cm
Ductal carcinoma in-situ with microinvasions (T1mic)
Breast cancers with an extensive in-situ ductal component (defined as >= 25% of the tumor volume and DCIS present within and in the surrounding normal breast tissue of the invasive tumor)
Must have pathology proven invasive ductal carcinoma (lobular is not allowed) and/or ductal carcinoma in situ (DCIS).
On histological examination, the tumor must be ductal carcinoma in situ (DCIS) or invasive adenocarcinoma of the breast
No prior breast carcinoma or ductal carcinoma in situ in the ipsilateral breast; patients with a local recurrence of a previously excised phyllodes tumor are eligible if the recurrence is in the area of the previous excision
Breast carcinoma or ductal carcinoma in situ in the ipsilateral breast
Ductal carcinoma in-situ or invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies; invasive lobular carcinomas are allowed
Prior history of invasive breast cancer or ductal breast carcinoma in situ (DCIS)
Ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS) or breast conserving treatment and hormonal therapy for DCIS or invasive breast cancer
On histologic examination, the tumor must be ductal carcinoma in situ (DCIS) and/or invasive breast carcinoma
The participant has breast biopsy consistent with ductal carcinoma in situ (DCIS)
Adequately treated breast ductal carcinoma in situ without evidence of disease
Subjects with ductal carcinoma in situ (DCIS)  that express HER-2 on 10% of the DCIS that have not had definitive surgery are diagnosed by core biopsy or needle-localized (NL) surgical biopsy with positive margins
Grade 1-3 invasive ductal, mammary, mucinous, tubular, colloidal, or pure ductal carcinoma in situ (DCIS) measuring =< 2.5 cm on final pathology (the tumor should be clinical stage T1N0M0 in patients electing brachytherapy in whom the catheter will be placed intraoperatively)
Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins)
Histologically-confirmed ductal carcinoma in situ (DCIS) or stage I-III invasive carcinoma of the breast; NOTE: women with history of breast cancer, radiation, or plastic surgery to the contralateral breast, or concurrent bilateral breast cancer, will not participate in the FNA portion of the study
Ductal carcinoma in situ (DCIS) or invasive ductal, medullary, papillary, mucinous (colloid), or tubular histologies
Pathologic T stage of Tis, T1, or T2 with total size of tumor =< 3 cm (this size criteria applies to both pure ductal carcinoma in situ [DCIS] and invasive tumors)
ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone, or
Synchronous bilateral breast cancer (invasive or ductal carcinoma in situ [DCIS])
Ductal carcinoma in situ (DCIS) or Stage I-III, primary invasive carcinoma of the breast
Curatively treated ductal carcinoma in situ of the breast;
Patients with history of breast cancer greater than 5 years from initial diagnosis and are disease free are eligible for the study; patients with history of ductal carcinoma in situ (DCIS) are eligible if there were treated with surgery alone
Patients must have a tissue diagnosis of low, intermediate or high grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion.
Patients with ductal carcinoma in situ undergoing either lumpectomy/radiation or mastectomy.
Diagnosis of ductal carcinoma in situ (DCIS) or stage I, II, or III breast cancer
Participants who have been diagnosed with ductal carcinoma in-situ (DCIS) or invasive breast cancer and have been offered lumpectomy or mastectomy for surgical treatment will be considered for the study
Ductal carcinoma in situ (DCIS) diagnosis
Ambulatory outpatients with breast (including ductal carcinoma in situ [DCIS]) cancer
Presence of a proportion of ductal carcinoma in situ (DCIS) in the core biopsy specimen which is compatible with extensive intraductal component (EIC)
Invasive or ductal carcinoma in situ (DCIS) breast cancer
Patients must not have previous personal history of breast cancer including ductal carcinoma in situ
Previous treatment for breast cancer including chemotherapy, endocrine therapy and radiotherapy; women with prior ductal breast carcinoma in situ (DCIS) who were treated with surgery only and whose treatment ended >= 2 years prior to enrollment are eligible for the trial
Women with a previous history of invasive breast cancer or bilateral ductal carcinoma in situ (DCIS) or current untreated DCIS; women with a history of cancer within the last 3 years, except for non-melanoma skin cancer; women with unilateral DCIS (with or without radiation therapy) are eligible as long as they have an unaffected breast
History of prior ductal carcinoma in situ (DCIS) treated within the past two years; patients completing all treatment for a previous diagnosis of DCIS over two years prior to the current diagnosis are eligible
Histologically confirmed invasive breast cancer or Ductal Carcinoma In Situ (DCIS)
History of any of the following:\r\n* Invasive breast cancer\r\n* Ductal breast carcinoma in situ (DCIS)\r\n* Flat epithelial atypia
DCIS or previous invasive ductal carcinoma.
Positive margins on ink after definitive surgery either for ductal carcinoma in situ (DCIS) or invasive cancer
Any personal history of cancer, including ductal carcinoma in situ (DCIS) and not including non-melanoma skin cancers
Subject must have biopsy-proven invasive ductal carcinoma or ductal carcinoma in situ of the breast
History of prior breast cancer, ductal carcinoma in situ
No patients with previous ipsilateral or contralateral invasive breast cancer or ductal carcinoma in situ (DCIS)
No or equivocal ER testing performed prior to surgery if biopsy indicates ductal carcinoma in situ
History of other malignancy in the past 2 years except non-melanomatous skin cancer, breast ductal carcinoma in situ (DCIS) and low-risk prostate adenocarcinoma
History of other malignancy in the past 2 years except non-melanomatous skin cancer, breast ductal carcinoma in situ (DCIS) and low-risk prostate adenocarcinoma
Subjects with a diagnosis of primary breast cancer or subjects with pure ductal carcinoma in situ (DCIS).
Diagnosed with incident, primary, invasive, ductal or lobular, or other epithelial malignancy, clinical stage I or II, ER positive or negative breast cancer, or ductal carcinoma in situ (DCIS)
Ductal carcinoma in situ
A primary diagnosis of stage 0 (ductal carcinoma in situ), 1, 2, or 3a breast cancer